In recent years, a steady increase in the microbial resistance to antibiotics has become a major threat to global public health. Experts have been warned of the return of pre-antibiotic era, due to an increasing resistance to most widely used treatments and a few new antibiotics in development. Antibiotic resistance accounts for 50,000 deaths per year in the US and Europe alone. Routine surgeries and minor infections might become life threatening if novel antibiotics are not developed. In spite of microbial resistance being a major concern, very few companies are actively involved in research. Mergers between pharmaceutical companies have also reduced the number and diversity of the research teams. However, developed countries with well-funded health care systems are taking preventive measures. Development of novel antibiotics against multi-drug resistant organisms may help the antibiotics market growth.
Drivers & Restraints:
The emergence of anti-MRSA/VRE drugs, development of generic drugs, and vulnerable aging population are the major drivers for the growth of antibiotics market. Market restraints include antibiotic resistance, fewer companies involved in active research, and the time taken for regulatory approval.
Global Antibiotics Market Segmentation:
Global antibiotics market is segmented by -
1. Type of antibiotics -
Global antibiotic market trends show that beta-lactams hold the largest share, led by sales of the latest-generation antibiotics in this class, like cefcapene, ceftriaxone, and cefuroxime. Macrolides hold the second largest share, due to a steady rise in their prescribed use across developing countries, as they are active against a range of common bacterial infections.
2. Spectrum -
Broad-spectrum antibiotics account for the highest market share, as they act against a range of disease-causing bacteria. Broad-spectrum antibiotics include cephalosporins, penicillin, fluoroquinolones, and tetracyclines. Aminoglycosides and sulfonamides are examples of narrow-spectrum antibiotics. The market has also been segmented by geography into North America, Europe, Asia-Pacific, and Rest of the World.
Key Players in the Study
Some of the largest market players in the antibiotics market are
Market analysis for the global antibiotics market, with region specific assessments and competition analysis.
Market definition along with the identification of key drivers, restraints opportunities and challenges.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the global antibiotics market.
Insights of the market in the regions that have the highest potential for growth and also identify the markets that are still untapped.
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. Research Methodology
2.2 Analysis Methodology
2.3 Econometric Forecast Model
3. Executive Summary
4. Key Inferences
5. Market Characterization
5.1 Current Market Scenario
5.2 Market Overview
5.2.1 Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis
188.8.131.52 Market Drivers
184.108.40.206.1 Emergence of Anti-MRSA/VRE Drugs
220.127.116.11.2 Development of Generic Drugs
18.104.22.168.3 Vulnerable Aging Population
22.214.171.124 Market Restraints
126.96.36.199.1 Antibiotic Resistance
188.8.131.52.2 Fewer Companies Involved in Active Research
184.108.40.206.3 Time Taken for Regulatory Approval
220.127.116.11.1 Development of Novel Antibiotics Against Multi-drug Resistant Organisms
5.2.2 Market Segmentation
18.104.22.168 By Type
22.214.171.124.8 Glycopeptide antibiotics
126.96.36.199.9 Lipopeptides antibiotics
188.8.131.52.10 Polypeptide antibiotics
184.108.40.206.12 Antitubercular drugs
220.127.116.11.13 Antileprotic drugs
18.104.22.168.14 Antifungal drugs
22.214.171.124.15 Antimalarial drugs
126.96.36.199.16 Anthelmintic drugs
188.8.131.52 By Spectrum
184.108.40.206.1 Broad-spectrum Antibiotics
220.127.116.11.2 Narrow-spectrum Antibiotics
18.104.22.168 By Geography
22.214.171.124.1 North America
126.96.36.199.2.5 Spain & Portugal
188.8.131.52.3.5 South Korea
184.108.40.206.4 The Middle East & Africa
220.127.116.11.4.2 South Africa
18.104.22.168.5 Latin America
6. Industry Analysis
6.1 Porterâ€™s Five Forces
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Consumers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitute Products and Services
6.1.5 Competitive Rivalry within the Industry
7. Competitive Landscape
7.1 Mergers & Acquisitions
7.2 Agreements, Collaborations & Partnerships
7.3 New Product Launches
7.4 Recommendations to New Market Players
8. Company Profiles
8.2 Johnson & Johnson
8.6 Bayer Healthcare AG
8.9 Abbott Laboratories
9. Future Outlook